June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Baseline characteristics of French patients with wet age-related macular degeneration (wAMD) enrolled in the LUMINOUS study.
Rocio Blanco-Garavito; Hassiba Oubraham; Benjamin Wolff; Salomon Y Cohen; Catherine P Garcher; Jean-Francois Korobelnik; Christian Delhay; Ramin Tadayoni; Audrey Derveloy; Eric H Souied; French LUMINOUS Group.
Author Affiliations & Notes
  • Rocio Blanco-Garavito
    Ophthalmology, Centre Hospitalier Intercommunal de Creteil, Creteil, France
  • Hassiba Oubraham
    Ophthalmology, Private Practice, Montargis, France
  • Benjamin Wolff
    Ophthalmology, Fondation Rothschild, Paris, France
  • Salomon Y Cohen
    Ophthalmology, Centre d'Imagerie et de Laser, Paris, France
  • Catherine P Garcher
    Ophthalmology, Centre Hospitalier Universitaire Dijon, Dijon, France
  • Jean-Francois Korobelnik
    Ophthalmology, Hopital Pellegrin, Bordeaux, France
  • Christian Delhay
    Ophthalmology, Centre d'ophtalmologie du Mené-Ténénio, Vannes, France
  • Ramin Tadayoni
    Ophthalmology, Hopital Lariboisiere, Paris, France
  • Audrey Derveloy
    Ophthalmology Division, Novartis Pharma SAS, 2 Rue Lionel Terray, France
  • Eric H Souied
    Ophthalmology, Centre Hospitalier Intercommunal de Creteil, Creteil, France
  • Footnotes
    Commercial Relationships Rocio Blanco-Garavito, BAYER (R), Novartis Pharma SAS (C); Hassiba Oubraham, Allergan (C), Bayer (C), Novartis Pharma SAS (C); Benjamin Wolff, Novartis Pharma SAS (C); Salomon Cohen, Alcon (C), Allergan (C), Bayer (C), Novartis Pharma SAS (C), Thea (C); Catherine Garcher, Alcon (C), Allergan (C), Allumera (C), Basuch and Lomb (C), Bausch and Lomb (C), Bayer (C), Novartis Pharma SAS (C), Thea (C); Jean-Francois Korobelnik, Alcon (C), Alimera (C), Allergan (C), Bayer (C), Horus Pharma (C), Novartis Pharma SAS (C), Roche (C), Thea Pharmaceuticals (C); Christian Delhay, Allergan (C), Bayer (C), Novartis (C); Ramin Tadayoni, Alcon (C), Alimera (C), Allergan (C), Bausch and Lomb (C), Bayer (C), Dorc (C), Novartis Pharma SAS (C), Sony (C), Takeda (C), Thrombogenics (C), Zeiss (C); Audrey Derveloy, Novartis Pharma SAS (E); Eric Souied, Allergan (C), Bayer (C), Novartis Pharma SAS (C), Thea (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5364. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Baseline characteristics of French patients with wet age-related macular degeneration (wAMD) enrolled in the LUMINOUS study.
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Rocio Blanco-Garavito, Hassiba Oubraham, Benjamin Wolff, Salomon Y Cohen, Catherine P Garcher, Jean-Francois Korobelnik, Christian Delhay, Ramin Tadayoni, Audrey Derveloy, Eric H Souied, French LUMINOUS Group.; Baseline characteristics of French patients with wet age-related macular degeneration (wAMD) enrolled in the LUMINOUS study.. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5364.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: To describe the baseline characteristics of the French enrolled wAMD patients in the LUMINOUS (NCT01318941) study.

Methods: LUMINOUS is an ongoing, global, 5-year multicenter, prospective, observational study to evaluate the long-term safety, effectiveness, treatment patterns and health-related quality-of-life associated with ranibizumab (RBZ) treatment in clinical practice for all licensed indications. Interim data are available for a total of 17,545 adult wAMD patients globally. We analyzed the baseline characteristics of the 469 wAMD patients enrolled in France prior to March 2014.

Results: In the French wAMD cohort, 16 (3.4%) patients were treatment naïve (T1), 452 (96.4%) had received prior ranibizumab treatment (T2), and 1 (0.2%) had previously received other ocular treatments for wAMD. The baseline characteristics of the French/global wAMD cohorts were: mean age 79.0/77.4 years and 32.4/42.0% were male. For the French/global wAMD cohorts, mean baseline visual acuity (VA, Early Treatment Diabetic Retinopathy Study [ETDRS] letter score) was 49.4/48.8 for T1 and 58.9/56.4 for T2; 68.9/42.4% had Pigment Epithelium Detachment (PED). Non-ocular comorbidities for the French/global wAMD patients included myocardial infarction (5.5/7.3%), stroke (5.5/5.6%), other thromboembolic events (4.9/4.9%), family history of coronary artery disease (14.1/14.9%), diabetes (10.7/14.5%), hypertension (51.4/56.7%), and obesity (BMI >30kg/m2; 11.5/10.0%). For those having received prior ranibizumab treatment, the mean duration of treatment was 2.5 years and the mean number of injections/year was 5.6.

Conclusions: The French wAMD patients enrolled in the LUMINOUS study were slightly older, had similar baseline VA, a greater proportion had PED, and a similar proportion had non-ocular comorbidities at baseline, compared to the global cohort. In both cohorts, prior ranibizumab treated patients had higher VA at baseline than treatment naïve patients. Future follow-up data from this cohort of French patients will provide an invaluable source of information from a diverse group of patients currently underrepresented in randomized clinical trials.

The Association for Research in Vision and Ophthalmology
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept